Product Description
Standard :In-house Standards
AI Product Description
*The following content is generated by AI and is for reference only.
Crisaborole is a novel, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of mild to moderate atopic dermatitis in patients aged three months and older. Its chemical identity is defined by the molecular formula C21H23N5O2 and the CAS registry number 1097168-42-1. Structurally, it belongs to the class of benzofuran derivatives, featuring a unique mechanism that distinguishes it from traditional corticosteroid therapies. By selectively inhibiting PDE4, Crisaborole increases intracellular cyclic adenosine monophosphate (cAMP) levels within inflammatory cells. This biochemical shift effectively suppresses the production of key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-4 (IL-4), and interferon-gamma, thereby reducing skin inflammation without the systemic absorption or side effects commonly associated with steroid use.
Clinically, Crisaborole ointment serves as a first-line therapy for managing acute flares and maintaining remission in atopic dermatitis. It offers a favorable safety profile, making it particularly suitable for sensitive areas such as the face, neck, and intertriginous regions where long-term steroid application might cause skin thinning or striae. Common adverse reactions are generally mild and localized, often presenting as transient application site pain, burning, or stinging sensations upon initial use. Unlike potent steroids, it does not carry risks of hypothalamic-pituitary-adrenal axis suppression or significant skin atrophy, allowing for flexible dosing schedules tailored to individual patient needs.
The development of Crisaborole represents a significant advancement in dermatological care, addressing the unmet need for effective non-hormonal treatments. Its approval has expanded therapeutic options for both pediatric and adult populations seeking to avoid the potential long-term complications of corticosteroids. As a small molecule drug, it demonstrates good skin penetration while minimizing systemic exposure. Ongoing research continues to explore its efficacy in broader inflammatory skin conditions, though its primary indication remains focused on atopic dermatitis management. With its distinct mode of action and robust safety data, Crisaborole stands as a cornerstone in modern eczema treatment protocols, empowering clinicians to provide personalized, effective care while prioritizing patient quality of life and long-term skin health.